Ankylosing Spondylitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Ankylosing Spondylitis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ankylosing Spondylitis: Overview
Ankylosing Spondylitis (AS) is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. Ankylosing Spondylitis also cause pain, inflammation in other parts of the body such as the shoulders, hips, ribs , heels and small joints of the hands and feet. In some cases, the eyes are also involved (known as iritis or uveitis). In more advanced cases, these inflammation can lead to new bone formation in the spine, causing sections of spine top fuse in fixed, immobile position. The hallmark feature of Ankylosing spondylitis is the involvement of sacroiliac (SI) joints during the progression of disease. Ankylosing Spondylitis (AS) symptoms occurs at any age, but they start occurring at the age of 45. It also affect children, called juvenile ankylosing spondylitis, and more commonly occur in boys than in girls.
'Ankylosing Spondylitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ankylosing Spondylitis Emerging Drugs
Further product details are provided in the repor
Ankylosing Spondylitis: Therapeutic Assessment
This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:
Ankylosing Spondylitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.
Ankylosing Spondylitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Ankylosing Spondylitis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ankylosing Spondylitis: Overview
Ankylosing Spondylitis (AS) is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. Ankylosing Spondylitis also cause pain, inflammation in other parts of the body such as the shoulders, hips, ribs , heels and small joints of the hands and feet. In some cases, the eyes are also involved (known as iritis or uveitis). In more advanced cases, these inflammation can lead to new bone formation in the spine, causing sections of spine top fuse in fixed, immobile position. The hallmark feature of Ankylosing spondylitis is the involvement of sacroiliac (SI) joints during the progression of disease. Ankylosing Spondylitis (AS) symptoms occurs at any age, but they start occurring at the age of 45. It also affect children, called juvenile ankylosing spondylitis, and more commonly occur in boys than in girls.
'Ankylosing Spondylitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis.
This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ankylosing Spondylitis Emerging Drugs
- Tofacitinib: Pfizer
- Bimekizumab: UCB
- Namilumab: Izana Bioscience
- KIN-1901: Kinevant Sciences
- AK111: Akeso Biopharma
Further product details are provided in the repor
Ankylosing Spondylitis: Therapeutic Assessment
This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ankylosing Spondylitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Subcutaneous
- Intravenous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Small molecule
- Recombinant fusion proteins
- Product Type
Ankylosing Spondylitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.
Ankylosing Spondylitis Report Insights
- Ankylosing Spondylitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ankylosing Spondylitis drugs?
- How many Ankylosing Spondylitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ankylosing Spondylitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Amgen
- Sun Pharma Global
- Jiangsu Hengrui Medicine Co.
- Izana Bioscience
- Suzhou Zelgen
- Iltoo Pharma
- Akeso Biopharma
- Kinevant Sciences
- Qyuns Therapeutics
- Enzene Biosciences
- Xbrane Biopharma
- Dice molecules
- Mycenax Biotech
- Nimbus Therapeutics
- Tofacitinib
- Apremilast
- Tildrakizumab
- SHR0302
- Namilumab
- Jaktinib
- AK111
- KIN-1901
- QX002N
Introduction
Executive Summary
Ankylosing Spondylitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ankylosing Spondylitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ankylosing Spondylitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ankylosing Spondylitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tofacitinib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KIN-1901: Kinevant Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ankylosing Spondylitis Key Companies
Ankylosing Spondylitis Key Products
Ankylosing Spondylitis- Unmet Needs
Ankylosing Spondylitis- Market Drivers and Barriers
Ankylosing Spondylitis- Future Perspectives and Conclusion
Ankylosing Spondylitis Analyst Views
Ankylosing Spondylitis Key Companies
Appendix
Executive Summary
Ankylosing Spondylitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ankylosing Spondylitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ankylosing Spondylitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ankylosing Spondylitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tofacitinib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KIN-1901: Kinevant Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ankylosing Spondylitis Key Companies
Ankylosing Spondylitis Key Products
Ankylosing Spondylitis- Unmet Needs
Ankylosing Spondylitis- Market Drivers and Barriers
Ankylosing Spondylitis- Future Perspectives and Conclusion
Ankylosing Spondylitis Analyst Views
Ankylosing Spondylitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ankylosing Spondylitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ankylosing Spondylitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ankylosing Spondylitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ankylosing Spondylitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
